Joe Roberts serves as the Interim Principal Financial Officer and Accounting Officer, as well as Controller, at Arcturus Therapeutics Holdings Inc., a leading messenger RNA (mRNA) medicines company. In this critical role, he oversees all financial reporting, accounting operations, internal controls, and compliance functions, ensuring the company's fiscal integrity amid rapid growth and clinical advancements. Appointed to the interim principal positions in early 2023, Roberts has been instrumental in steering Arcturus through key milestones, including the successful commercialization preparations for its COVID-19 vaccine candidate and ongoing pipeline development for rare diseases. With over 20 years of experience in finance and accounting within the biotechnology and pharmaceutical sectors, Roberts brings a proven track record of excellence. Prior to joining Arcturus in 2020, he held senior finance roles at several prominent biotech firms, including VP of Finance at a clinical-stage oncology company where he managed multi-million-dollar funding rounds and SEC filings. A Certified Public Accountant (CPA), he began his career at Deloitte, honing his expertise in audit and advisory services for life sciences clients. Roberts' achievements include leading Arcturus' financial preparations for its 2021 SPAC merger with Velocity Acquisition Corp., which resulted in a Nasdaq listing under the ticker ARCT, and implementing robust ERP systems that enhanced operational efficiency by 30%. His strategic foresight has supported over $500 million in capital raises, positioning Arcturus as a frontrunner in lipid nanoparticle-delivered mRNA therapeutics.